Other scientific trials in clients with non-Hodgkin's lymphoma [24] and clients with State-of-the-art malignancy [fourteen] have proven also that zosuquidar did not appreciably have an affect on the pharmacokinetics of doxorubicin and had moderate effects within the pharmacokinetics of vincristine. These clinical trials authorized that zosuquidar c